AlphaStocks
5.3
Consider Buy

Abbott Laboratories (ABT)

As of Sep 20, 2026, Abbott Laboratories (ABT) scores 5.3/10 on AlphaStocks' five-model composite, #85 of 168 Health Care stocks. At $103, ABT trades 4% below its model fair value of $107.

Health Care / Health Care Equipment

S&P 500

$102.57

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#85out of 168 in Health Care

Is ABBOTT LABORATORIES a Good Investment in 2026?

ABBOTT LABORATORIES (ABT) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Buffett model rates ABBOTT LABORATORIES as Strong. The Lynch model is the least favorable, rating it Neutral. ABBOTT LABORATORIES currently trades 4% below its estimated fair value of $107. ABBOTT LABORATORIES ranks #85 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E27.5ROE12.7Market Cap179BDiv Yield2.5

Estimated Fair Value

$107.104% below

Trading near estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

88% above fair value

Lynch

Neutral

PEG 3.4 · Stalwart

Greenblatt

Attractive

Earnings yield 7.0% · ROC 55%

Frequently Asked Questions

Is ABBOTT LABORATORIES (ABT) a good investment?
As of Sep 20, 2026, Abbott Laboratories (ABT) scores 5.3/10 on AlphaStocks' five-model composite, #85 of 168 Health Care stocks. At $103, ABT trades 4% below its model fair value of $107. That score is below average, suggesting caution.
What is ABBOTT LABORATORIES's Piotroski F-Score?
ABBOTT LABORATORIES's Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ABT overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $107, ABT appears undervalued. The stock currently trades 4% below its estimated fair value. Trading near estimated fair value.
How does ABT compare to other Health Care stocks?
ABBOTT LABORATORIES ranks #85 out of 168 stocks in the Health Care sector, placing it in the top 51% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ABT?
AlphaStocks evaluates ABT using five proven investment models. Piotroski: Attractive; Buffett: Strong; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 5.3/10.

Similar Stocks

INSPUFPTBDX

Compare ABT with

ABT vs INSPABT vs UFPTABT vs BDXABT vs AZNABT vs VALABT vs FTIABT vs PARRABT vs MDT

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer